Activation of GPR55 Receptors Exacerbates oxLDL-Induced Lipid Accumulation and Inflammatory Responses, while Reducing Cholesterol Efflux from Human Macrophages
暂无分享,去创建一个
[1] M. De Bardi,et al. The differential characterization of GPR55 receptor in human peripheral blood reveals a distinctive expression in monocytes and NK cells and a proinflammatory role in these innate cells. , 2015, International immunology.
[2] P. Aukrust,et al. Interleukin-10 increases reverse cholesterol transport in macrophages through its bidirectional interaction with liver X receptor α. , 2014, Biochemical and biophysical research communications.
[3] A. McAinch,et al. A potential role for GPR55 in the regulation of energy homeostasis. , 2014, Drug discovery today.
[4] F. Fezza,et al. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor. , 2014, Atherosclerosis.
[5] P. Flatt,et al. Evaluation of the insulin releasing and antihyperglycaemic activities of GPR55 lipid agonists using clonal beta‐cells, isolated pancreatic islets and mice , 2013, British journal of pharmacology.
[6] K. Mackie,et al. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice , 2013, Neuropharmacology.
[7] M. Waldhoer,et al. A Selective Antagonist Reveals a Potential Role of G Protein–Coupled Receptor 55 in Platelet and Endothelial Cell Function , 2013, The Journal of Pharmacology and Experimental Therapeutics.
[8] Albina Arjuman,et al. Effect of IL-10 on LOX-1 expression, signalling and functional activity: An atheroprotective response , 2013, Diabetes & vascular disease research.
[9] D. Centonze,et al. Distinct modulation of human myeloid and plasmacytoid dendritic cells by anandamide in multiple sclerosis , 2013, Annals of neurology.
[10] D. Rusakov,et al. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses , 2013, Proceedings of the National Academy of Sciences.
[11] S. Steffens,et al. Targeting cannabinoid receptor CB2 in cardiovascular disorders: promises and controversies , 2012, British journal of pharmacology.
[12] P. Ricciardi-Castagnoli,et al. NFAT control of innate immunity. , 2012, Blood.
[13] M. Malagón,et al. The atypical cannabinoid O‐1602 stimulates food intake and adiposity in rats , 2012, Diabetes, obesity & metabolism.
[14] J. Moreno-Navarrete,et al. The l-α-Lysophosphatidylinositol/GPR55 System and Its Potential Role in Human Obesity , 2012, Diabetes.
[15] S. Zimmer,et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. , 2011, Journal of molecular and cellular cardiology.
[16] S. Romero-Zerbo,et al. A role for the putative cannabinoid receptor GPR55 in the islets of Langerhans. , 2011, The Journal of endocrinology.
[17] F. Basile,et al. Endocannabinoids inhibit release of nerve growth factor by inflammation-activated mast cells. , 2011, Biochemical pharmacology.
[18] M. Caron,et al. Screening for Selective Ligands for GPR55 - Antagonists , 2011 .
[19] H. van Eenennaam,et al. Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice , 2011, The open cardiovascular medicine journal.
[20] M. Maccarrone,et al. Endomorphin-1 prevents lipid accumulation via CD36 down-regulation and modulates cytokines release from human lipid-laden macrophages , 2011, Peptides.
[21] D. Thewke,et al. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. , 2010, Atherosclerosis.
[22] W. Graier,et al. GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells , 2010, British journal of pharmacology.
[23] J. Groopman,et al. Endocannabinoid‐like N‐arachidonoyl serine is a novel pro‐angiogenic mediator , 2010, British journal of pharmacology.
[24] M. Abood,et al. Pharmacological characterization of GPR55, a putative cannabinoid receptor. , 2010, Pharmacology & therapeutics.
[25] R. de Caterina,et al. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability. , 2010, Cardiovascular research.
[26] G. Bernardi,et al. Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors , 2010, PloS one.
[27] K. Tan,et al. ABCG1 mediated oxidized LDL-derived oxysterol efflux from macrophages. , 2009, Biochemical and biophysical research communications.
[28] K. Mackie,et al. Regulation of MAP Kinase–Directed Mitogenic and Protein Kinase B–Mediated Signaling by Cannabinoid Receptor Type 1 in Skeletal Muscle Cells , 2009, Diabetes.
[29] K. Mackie,et al. The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo , 2009, Proceedings of the National Academy of Sciences.
[30] Jerzy Bełtowski,et al. Adverse effects of statins - mechanisms and consequences. , 2009, Current drug safety.
[31] R. Ross. The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.
[32] A. Irving,et al. The GPR55 ligand L‐α‐lysophosphatidylinositol promotes RhoA‐dependent Ca2+ signaling and NFAT activation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[33] B. Staels,et al. Rimonabant, a Selective Cannabinoid CB1 Receptor Antagonist, Inhibits Atherosclerosis in LDL Receptor–Deficient Mice , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[34] A. Modesti,et al. Endomorphin-1 Inhibits the Activation and the Development of a Hyporesponsive-like Phenotype in Lipopolysaccharide-Stimulated THP-1 Monocytes , 2008, International journal of immunopathology and pharmacology.
[35] I. Chessell,et al. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.
[36] V. Izzi,et al. Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages , 2008, Regulatory Peptides.
[37] Markus Waldeck-Weiermair,et al. Integrin clustering enables anandamide-induced Ca2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression , 2008, Journal of Cell Science.
[38] F. Mach,et al. The Role of the Endocannabinoid System in Atherosclerosis , 2008, Journal of neuroendocrinology.
[39] Juliette Martin,et al. CD36 and macrophages in atherosclerosis. , 2007, Cardiovascular research.
[40] A. Tall,et al. Cholesterol-induced Apoptotic Macrophages Elicit an Inflammatory Response in Phagocytes, Which Is Partially Attenuated by the Mer Receptor* , 2006, Journal of Biological Chemistry.
[41] J. Després,et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. , 2005, The New England journal of medicine.
[42] H. Brewer,et al. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver Published, JLR Papers in Press, July 16, 2005. DOI 10.1194/jlr.M500080-JLR200 , 2005, Journal of Lipid Research.
[43] M. Bennett,et al. Tumor Necrosis Factor-&agr; Promotes Macrophage-Induced Vascular Smooth Muscle Cell Apoptosis by Direct and Autocrine Mechanisms , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[44] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[45] Seth M. Klein,et al. Scavenger receptor class B type I affects cholesterol homeostasis by magnifying cholesterol flux between cells and HDL. , 2001, Journal of lipid research.
[46] Y. Pak,et al. Role of endocytosis in the transactivation of nuclear factor-κB by oxidized low-density lipoprotein , 2000 .
[47] A. Tall,et al. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. , 2000, The Journal of biological chemistry.
[48] M. Seishima,et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. , 2000, Atherosclerosis.
[49] R. Evans,et al. Oxidized LDL Regulates Macrophage Gene Expression through Ligand Activation of PPARγ , 1998, Cell.
[50] R. Evans,et al. PPARγ Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL , 1998, Cell.
[51] M. Feldmann,et al. Beneficial effects of tumour necrosis factor‐alpha (TNF‐α) blockade in rheumatoid arthritis (RA) , 1995, Clinical and experimental immunology.
[52] E. Kostenis,et al. Gpr55 Regulates Cannabinoid 2 Receptor-mediated Responses in Human Neutrophils Ukpmc Funders Group Author Manuscript Introduction , 2022 .
[53] P. Pacher. Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? , 2009, Arteriosclerosis, thrombosis, and vascular biology.
[54] C. Palumbo,et al. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. , 2009, International journal of oncology.
[55] D. McHugh,et al. Endogenous cannabinoids and neutrophil chemotaxis. , 2009, Vitamins and hormones.
[56] Y. Pak,et al. Role of endocytosis in the transactivation of nuclear factor-kappaB by oxidized low-density lipoprotein. , 2000, Biochemical Journal.
[57] R. Evans,et al. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. , 1998, Cell.
[58] Robert Lipsky,et al. The carboxyl-terminal cytoplasmic domain of CD36 is required for oxidized low-density lipoprotein modulation of NF-kappaB activity by tumor necrosis factor-alpha. , 1997, Receptors & signal transduction.